Uma Borate
Clinical trials sponsored by Uma Borate, explained in plain language.
-
New combo therapy targets Hard-to-Cure leukemia
Disease control Recruiting nowThis early-phase study tests whether combining two targeted drugs, SNDX-5613 and gilteritinib, is safe and effective for adults with a specific type of acute myeloid leukemia (AML) that has returned or not responded to treatment. The drugs work by blocking different signals that …
Phase: PHASE1 • Sponsor: Uma Borate • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug combo aims to shrink Hard-to-Treat blood cancers
Disease control Recruiting nowThis study tests a new antibody called axatilimab, given with or without the chemotherapy drug azacitidine, for people with advanced myeloproliferative neoplasms (MPN), MPN/MDS overlap, or high-risk chronic myelomonocytic leukemia (CMML). The goal is to find the safest dose and s…
Phase: PHASE1, PHASE2 • Sponsor: Uma Borate • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Anti-Inflammatory drug could stop blood cancer before it starts
Prevention Recruiting nowThis phase II trial tests whether canakinumab, a drug that reduces inflammation, can prevent blood cancer in people with CCUS—a condition where low blood counts and genetic mutations raise cancer risk. About 110 adults with high-risk CCUS will receive either canakinumab or a plac…
Phase: PHASE2 • Sponsor: Uma Borate • Aim: Prevention
Last updated Jun 27, 2026 08:08 UTC